Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03354663 · ClinicalTrials.gov registry record · NA
TactiSense IDE Trial of TactiCath SE for Paroxysmal Atrial Fibrillation
A NA study, sponsored by Abbott Medical Devices.
- Completed
- Registry status
- NA
- Development phase
- 156
- Enrollment target
NCT03354663 is a NA study that has completed, run by Abbott Medical Devices. The registered enrollment target is 156 participants.
The verdict
NCT03354663, a NA study, has completed, sponsored by Abbott Medical Devices.
- COMPLETED
- Registry status
- NA
- Development phase
- 156 participants
- Enrollment target
Study Summary
This clinical investigation is intended to demonstrate the acute safety and effectiveness of ablation with the TactiCath™ Contact Force Ablation Catheter, Sensor Enabled™ (TactiCath SE) for the treatment of drug refractory recurrent symptomatic paroxysmal atrial fibrillation (PAF). This clinical investigation will be conducted under an investigational device exemption (IDE) and is intended to support market approval of the TactiCath SE ablation catheter in the United States. One hundred fifty six (156) subjects will be enrolled at up to 35 investigational sites in the US, Europe, and Australia. This clinical investigation is sponsored by Abbott.
Interventions
- DEVICE TactiCath SE
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 156 participants |
| Start Date | 2017-12-11 |
| Est. Completion | 2019-10-30 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03354663
The ClinicalTrials.gov registry entry for NCT03354663 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 156 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Abbott Medical Devices, which has 261 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which TactiCath SE is the first listed.
NCT03354663 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03354663 about?
NCT03354663 is a clinical study titled "TactiSense IDE Trial of TactiCath SE for Paroxysmal Atrial Fibrillation". This clinical investigation is intended to demonstrate the acute safety and effectiveness of ablation with the TactiCath™ Contact Force Ablation Catheter, Sensor Enabled™ (TactiCath SE) for the treatment of drug refractory recurrent symptomatic paroxysmal atrial fibrillation (PAF). This clinical inv...
What is the current status of trial NCT03354663?
This trial is currently completed. It is a NA study. The enrollment target is 156 participants. The study started on 2017-12-11. Estimated completion is 2019-10-30.
What interventions are being tested in trial NCT03354663?
The interventions under investigation include: TactiCath SE (DEVICE).
Who is sponsoring clinical trial NCT03354663?
This trial is sponsored by Abbott Medical Devices, which has 261 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.